Prospective Database for Chronic Myelogenous Leukemia
Not Applicable
- Conditions
- Leukemia, Myeloid, Chronic
- Registration Number
- NCT00538447
- Brief Summary
Prospective Database for Chronic Myelogenous Leukemia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- Patients with CML
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method safety and efficacy 10 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of BCR-ABL inhibition are explored in NCT00538447 CML database?
How does NCT00538447 compare tyrosine kinase inhibitors to standard CML treatment outcomes?
Which biomarkers in NCT00538447 correlate with response to imatinib or dasatinib in CML patients?
What adverse events were reported in NCT00538447 for CML therapies and their management strategies?
What combination therapies with tyrosine kinase inhibitors are evaluated in NCT00538447 CML study?